Frontlight ResearchEarly access
Lung cancer trials in China
962 of 1144 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 2Active, not recruitingStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Where
- Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanjing, Shanghai, Shenyang, Wuhan, Zhengzhou
- Age
- 18 years and over
- People
- 128 worldwide
- Run by
- Teligene US
See details and how to joinNCT05168566 - Phase 1/2Taking peopleA Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Where
- Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Linyi, Nanchang, Shanghai, Taizhou, Wuhan
- Age
- 18 years to 75 years
- People
- 570 worldwide
- Run by
- Tyligand Pharmaceuticals (Suzhou) Limited
See details and how to joinNCT06385925 - Phase 2/3Taking peopleSFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
- Where
- Nanchang
- Age
- 18 years to 85 years
- People
- 30
- Run by
- Second Affiliated Hospital of Nanchang University
See details and how to joinNCT07131319 - Phase 3Taking peopleMK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)
- Where
- Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hshijiazhuang, Jinan, Kunming, Nanchang, Nanning, Ningbo, Shanghai, Urumuqi, Wuhan
- Age
- 18 years and over
- People
- 400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07431827 · EU 2024-517337-41-00 - Phase 1/2Taking peopleSumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
- Where
- Beijing
- Age
- 18 years and over
- People
- 208 worldwide
- Run by
- Full-Life Technologies UK Limited
See details and how to joinNCT07873450 - Phase 1Taking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Changsha, Chengdu, Guangzhou, Nanjing, Wenzhou
- Age
- 18 years and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - Phase 3Taking peopleA Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Anyang, Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Linyi, Liuzhou, Luoyang, Nanchang, Nanjing, Nanning, Nantong, Shanghai, Shantou, Taiyuan, Taizhou, Tianjin, Weifang, Wuhan, Xiamen, Xi’an, Xiangyang, Zhengzhou
- Age
- 18 years to 100 years
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356 · EU 2022-501863-41-00 - Phase 2Taking peopleSubstudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
- Where
- Beijing, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Zhengzhou
- Age
- 18 years and over
- People
- 144 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780098 · EU 2024-518839-11-00 - Phase 2/3Taking peopleA Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Linyi, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Taiyuan, Wuhan, Xiamen, Xi'an, Zhengzhou
- Age
- 18 years and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745 · EU 2025-521511-40-00 - Phase 1/2Taking peopleA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Where
- Baoding, Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jinan, Nanchang, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xiangyang, Xinxiang, Xuzhou, Yangzhou
- Age
- 18 years and over
- People
- 880 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07111520 · EU 2024-519344-32-00 - No phaseTaking peopleYSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 308
- Run by
- LI FENG
See details and how to joinNCT07390565 - Phase 2Not yet taking people in ChinaClinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer
- Where
- Guiyang
- Age
- 18 years to 75 years
- People
- 40
- Run by
- Guizhou Medical University
See details and how to joinNCT07936578 - Phase 1CompletedBeamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Where
- Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Nanning, Shanghai, Wuhan, Xiamen, Zhengzhou
- Age
- 18 years and over
- People
- 554 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT04886804 · EU 2024-511246-39-00 - Phase 1/2Active, not recruitingFirst in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Beijing, Changsha, Chengdu, Fuzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai, Taizhou, Wuhan
- Age
- 18 years and over
- People
- 430 worldwide
- Run by
- Bayer
See details and how to joinNCT05099172 · EU 2023-503795-24-00 - Phase 3Active, not recruitingA Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jiamusi, Jinan, Kunming, Linhai, Linyi, Nanchang, Nanjing, Neijiang, Shanghai, Suzhou, Taiyuan, Ürümqi, Wenzhou, Wuhan, Wuxi, Xiamen, Xi'an, Xian, Zhengzhou
- Age
- 18 years and over
- People
- 348 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06345729 · EU 2023-507776-42-00 - Phase 3Taking peopleThis is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Where
- Beijing, Changchun, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Huizhou, Jinan, Kunming, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Taizhou, Tianjin, Wenzhou, Wuhan, Xi’an, Xuzhou, Zhengzhou
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Pfizer
See details and how to joinNCT06758401 · EU 2024-517968-36-00 - Phase 1/2Taking peopleA Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- Where
- Beijing, Hangzhou, Nanjing, Wuhan
- Age
- 18 years and over
- People
- 450 worldwide
- Run by
- Bayer
See details and how to joinNCT06914128 · EU 2025-520623-24-00 - Phase 2/3Taking peopleStudy of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- Where
- Anyang, Beijing, Changchun, Changsha, Chongqing, Fuzhou, Hangzhou, Jiangmen, Jinan, Jingzhou, Linhai, Luoyang, Nanchang, Nanning, Shanghai, Shenyang, Taiyuan, Wuhan, Xuzhou
- Age
- 18 years and over
- People
- 661 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07100080 - Phase 3Taking peopleA Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
- Where
- Beijing, Changsha, Gannan, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Wuhan, Zhengzhou
- Age
- 18 years to 80 years
- People
- 400
- Run by
- InxMed (Shanghai) Co., Ltd.
See details and how to joinNCT07174908 - Phase 3Taking peopleA Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Where
- Beijing, Changsha, Chengdu, Chongqing, Fujian, Fuzhou, Guangzhou, Hangzhou, Hefei, Jiamusi, Kunming, Linyi, Nanchang, Nanjing, Nanning, Shanghai, Taiyuan, Taizhou, Wuhan, Xi'an, Zhengzhou
- Age
- 18 years and over
- People
- 675 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07190248 · EU 2024-514500-14-00 - Phase 1/2Taking peopleDual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
- Where
- Shenzhen
- Age
- 18 years to 75 years
- People
- 60
- Run by
- Beijing Biotech
See details and how to joinNCT07480213 - Phase 3Taking peopleA Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Where
- Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guilin, Hangzhou, Hefei, Jinan, Linhai, Nanjing, Nanning, Shanghai, Shijiazhuang, Taiyuan, Ürümqi, Wenzhou, Wuhan, Xiamen
- Age
- 18 years and over
- People
- 310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07554339 · EU 2025-522038-29-00 - Phase 3Taking peopleA Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in Non-small Cell Lung Cancer (NSCLC)
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 586
- Run by
- CSPC Megalith Biopharmaceutical Co.,Ltd.
See details and how to joinNCT07672223 - Phase 1/2Not yet taking people in ChinaDAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
- Where
- Nanning, Shanghai
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00 - Phase 2/3Taking peopleA Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 166
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07739186